Toronto Dominion Bank Has $18.40 Million Stock Holdings in Indivior PLC (NASDAQ:INDV)

Toronto Dominion Bank lowered its position in Indivior PLC (NASDAQ:INDV) by 45.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,141,377 shares of the company’s stock after selling 953,488 shares during the quarter. Toronto Dominion Bank owned 0.83% of Indivior worth $18,399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in Indivior during the 2nd quarter worth approximately $188,000. VELA Investment Management LLC bought a new stake in shares of Indivior in the second quarter worth $235,000. XTX Topco Ltd acquired a new stake in Indivior in the second quarter valued at $249,000. Chilton Investment Co. Inc. bought a new position in Indivior during the 4th quarter worth $263,000. Finally, ADAR1 Capital Management LLC acquired a new position in Indivior during the 4th quarter worth about $368,000. Institutional investors own 60.33% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Craig Hallum lowered their price objective on Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. Piper Sandler restated an “overweight” rating and set a $22.00 price target on shares of Indivior in a report on Friday, September 13th.

Indivior Price Performance

INDV stock opened at $9.92 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 992.00 and a beta of 0.68. The company’s fifty day simple moving average is $11.63 and its 200 day simple moving average is $15.62. Indivior PLC has a 12-month low of $9.05 and a 12-month high of $23.22.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The company had revenue of $299.00 million for the quarter, compared to the consensus estimate of $285.90 million. On average, analysts expect that Indivior PLC will post 1.7 earnings per share for the current year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.